SecBot SecBot
SECBOTREPLAY Home › Report › EWTX

EWTX · Edgewise Therapeutics is holding its 2026 Annual Meeting where…

Edgewise Therapeutics, Inc. · DEFA14A filed Apr 23, 2026 at 16:07 ET

At the news

NEUTRALIMPACT 2/10

DEFA14A filed Apr 23, 2026 at 16:07 ET

Edgewise Therapeutics is holding its 2026 Annual Meeting where shareholders are asked to vote on three proposals: electing three director nominees, ratifying KPMG LLP as the independent auditor, and approving the compensation of named executive officers. The filing is a definitive proxy statement filed by the company, indicating standard, routine corporate governance matters.

  • The filing is a DEFA14A, a definitive proxy statement for the 2026 Annual Meeting.
  • Three proposals are on the ballot: election of directors (Laura Brege, Badreddin Edris, Jonathan Root), ratification of KPMG LLP as auditors, and an advisory vote on executive compensation.
  • The company is requesting votes by June 3, 2026, for a meeting on June 4, 2026.
  • The filing was made by the registrant (Edgewise Therapeutics, Inc.), not a dissident party.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access